Agents targeting the epidermal growth factor receptor–mediated (EGFR-mediated) signaling pathway are increasingly used for the treatment of advanced lung, pancreatic, colorectal, and head and neck cancers, which benefit from exacerbated EGFR activity for their growth and survival (1, 2). Here, EGFR is linked to head and neck cancer.